Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Zacks Investment Research to Sell

Monte Rosa Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Monte Rosa Therapeutics Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Zacks Investment Research to Sell